This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Collen, D. Articles by Verstreken, M. Search for Related Content PubMed PubMed Citation Articles by Collen, D. Articles by Verstreken, M. Pubmed/NCBI databases Substance via MeSH

(Circulation. 1996;94:197-206.)
© 1996 American Heart Association, Inc.

Articles

Recombinant Staphylokinase Variants With Altered Immunoreactivity

I: Construction and Characterization

Desire Collen, MD, PhD; Ria Bernaerts, PhD; Paul Declerck, PhD; Frans De Cock; Edward Demarsin; Stephane Jenne; Yves Laroche, PhD; Henri R. Lijnen, PhD; Karen Silence, PhD; Maria Verstreken

the Center for Molecular and Vascular Biology, University of Leuven (Belgium).

Correspondence to D. Collen, MD, PhD, Center for Molecular and Vascular Biology, University of Leuven, Campus Gasthuisberg O&N, Herestr 49, B-3000 Leuven, Belgium. E-mail desire.collen@med.kuleuven.ac.be.

Background Recombinant staphylokinase offers promise for thrombolytic therapy in acute myocardial infarction, but it is immunogenic. Although reduced immunogenicity of heterologous proteinaceous drugs by protein engineering has not previously been reported, an attempt was made to achieve this in staphylokinase by site-specific mutagenesis.

Methods and Results Biospecific interaction analysis of a panel of 17 murine monoclonal antibodies against recombinant staphylokinase (SakSTAR variant) identified three nonoverlapping immunodominant epitopes, two of which could be eliminated by substitution mutagenesis of clusters of two or three charged amino acids with alanine. Circulating anti-staphylokinase antibodies elicited in patients by treatment with SakSTAR were incompletely (<90%) absorbed by these mutants. Therefore, the combination variants K35A,E38A,K74A,E75A,R77A (SakSTAR.M38) and K74A,E75A,R77A,E80A,D82A (SakSTAR.M89) were constructed, expressed in Escherichia coli, highly purified by ion-exchange and hydrophobic interaction chromatography, and characterized. These variants had specific activities that were approximately half that of SakSTAR, and they combined the reduced reactivity with the panels of monoclonal antibodies of their parent molecules. Absorption of circulating antibodies elicited in patients by treatment with SakSTAR was incomplete in 13 of 16 patients (median values, 68% and 65% with SakSTAR.M38 and SakSTAR.M89, respectively).

Conclusions SakSTAR contains three immunodominant epitopes, two of which were eliminated by site-directed mutagenesis, yielding combination mutants with relatively maintained specific activities that were not recognized by a significant fraction of the antibodies elicited in patients by treatment with wild-type SakSTAR. These mutants appear to be suitable for more detailed investigation of their thrombolytic and antigenic properties.

Key Words: thrombolysis • reperfusion • plasminogen activators • immunology • antigens

This article has been cited by other articles:

				P. A. M. Warmerdam, K. Vanderlick, P. Vandervoort, H. De Smedt, S. Plaisance, M. De Maeyer, and D. Collen Staphylokinase-Specific Cell-Mediated Immunity in Humans J. Immunol., January 1, 2002; 168(1): 155 - 161. [Abstract] [Full Text] [PDF]

				J. Llevadot, R. P. Giugliano, and E. M. Antman Bolus Fibrinolytic Therapy in Acute Myocardial Infarction JAMA, July 25, 2001; 286(4): 442 - 449. [Abstract] [Full Text] [PDF]

				Y. Laroche, S. Heymans, S. Capaert, F. De Cock, E. Demarsin, and D. Collen Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes Blood, August 15, 2000; 96(4): 1425 - 1432. [Abstract] [Full Text] [PDF]

				A.-P. Bijnens, A. Gils, I. Knockaert, J. M. Stassen, and P. J. Declerck Importance of the Hinge Region between alpha -Helix F and the Main Part of Serpins, Based upon Identification of the Epitope of Plasminogen Activator Inhibitor Type 1 Neutralizing Antibodies J. Biol. Chem., February 25, 2000; 275(9): 6375 - 6380. [Abstract] [Full Text] [PDF]

				S. Vanwetswinkel, S. Plaisance, Z. Zhi-yong, I. Vanlinthout, K. Brepoels, I. Lasters, D. Collen, and L. Jespers Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase Blood, February 1, 2000; 95(3): 936 - 942. [Abstract] [Full Text] [PDF]

				S. Jenne, K. Brepoels, D. Collen, and L. Jespers High Resolution Mapping of the B Cell Epitopes of Staphylokinase in Humans Using Negative Selection of a Phage-Displayed Antigen Library J. Immunol., September 15, 1998; 161(6): 3161 - 3168. [Abstract] [Full Text] [PDF]

				D. Collen, F. De Cock, E. Demarsin, S. Jenne, I. Lasters, Y. Laroche, P. Warmerdam, and L. Jespers Recombinant Staphylokinase Variants With Altered Immunoreactivity: III: Species Variability of Antibody Binding Patterns Circulation, January 21, 1997; 95(2): 455 - 462. [Abstract] [Full Text]

				D. Collen, L. Stockx, H. Lacroix, R. Suy, and S. Vanderschueren Recombinant Staphylokinase Variants With Altered Immunoreactivity: IV: Identification of Variants With Reduced Antibody Induction but Intact Potency Circulation, January 21, 1997; 95(2): 463 - 472. [Abstract] [Full Text]